Summary
Regeneron Pharmaceuticals, Inc. reported a notable increase in revenues for the six months ended June 30, 2019, reaching $3.65 billion, up from $3.12 billion in the prior year period. This growth was primarily driven by a strong performance in net product sales, particularly EYLEA in the U.S., and increased collaboration revenue from Sanofi and Bayer. Despite revenue growth, net income saw a significant decrease to $654.2 million from $1.03 billion in the same period last year. This decline is largely attributable to a substantial increase in research and development (R&D) expenses, which more than doubled to $1.69 billion, heavily impacted by a $400 million upfront payment made to Alnylam Pharmaceuticals for a new collaboration. The company's balance sheet shows an increase in total assets to $13.17 billion from $11.73 billion, bolstered by higher marketable securities and property, plant, and equipment, though cash and cash equivalents decreased. Key operational highlights include continued strong performance of EYLEA and significant advancements in the clinical pipeline for several key products like Dupixent and Libtayo, with regulatory submissions and approvals noted. The company also advanced its collaboration strategy with the Alnylam deal. However, investors should be mindful of the increased R&D spending, potential litigation risks (particularly concerning Praluent and EYLEA patents), and the company's continued reliance on key collaborations, especially with Sanofi and Bayer, for revenue generation and market access.
Financial Highlights
42 data points| Revenue | $1.58B |
| R&D Expenses | $885.50M |
| SG&A Expenses | $294.60M |
| Operating Expenses | $1.26B |
| Operating Income | $315.60M |
| Interest Expense | $8.00M |
| Net Income | $193.10M |
| EPS (Basic) | $1.77 |
| EPS (Diluted) | $1.68 |
| Shares Outstanding (Basic) | 109.20M |
| Shares Outstanding (Diluted) | 114.60M |
Key Highlights
- 1Total revenues increased by 17.2% to $3.65 billion for the six months ended June 30, 2019, compared to $3.12 billion for the same period in 2018.
- 2Net income decreased by 36.5% to $654.2 million for the six months ended June 30, 2019, compared to $1.03 billion in the prior year period.
- 3Research and development expenses significantly increased by 64.5% to $1.69 billion for the six months ended June 30, 2019, largely due to a $400 million upfront payment to Alnylam.
- 4Net product sales of EYLEA in the U.S. increased by 13.1% to $2.23 billion for the six months ended June 30, 2019.
- 5Sanofi collaboration revenue increased by 39.2% to $595.5 million for the six months ended June 30, 2019.
- 6The company's cash and cash equivalents decreased to $1.05 billion as of June 30, 2019, from $1.47 billion as of December 31, 2018.
- 7Regeneron continues to advance its pipeline with key products like Dupixent and Libtayo showing progress in regulatory filings and indications.